Last reviewed 2026-04-19 · How we verify

CYCLOPENTHIAZIDE

Phase 2 active Small molecule

CYCLOPENTHIAZIDE is a cyclopenthiazide drug. It is currently in Phase 2 development.

Cyclopenthiazide works by blocking the reabsorption of sodium in the kidneys, leading to increased urine production.

Cyclopenthiazide is a small molecule diuretic drug in the cyclopenthiazide class. It is used to treat hypertension and edema by increasing urine production. The commercial status of cyclopenthiazide is unknown, but it is likely available as a generic medication. Key safety considerations include potential electrolyte imbalances and dehydration. Cyclopenthiazide is a thiazide-like diuretic that works by inhibiting sodium reabsorption in the kidneys.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CYCLOPENTHIAZIDE
Drug class	cyclopenthiazide
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Think of it like a sponge: when you block the sponge's ability to absorb water, it gets too full and spills over. In the kidneys, cyclopenthiazide blocks the sponge-like cells from absorbing too much sodium, causing the body to get rid of excess sodium and water through urine.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CYCLOPENTHIAZIDE CI brief — competitive landscape report
CYCLOPENTHIAZIDE updates RSS · CI watch RSS

Frequently asked questions about CYCLOPENTHIAZIDE

What is CYCLOPENTHIAZIDE?

CYCLOPENTHIAZIDE is a cyclopenthiazide drug.

How does CYCLOPENTHIAZIDE work?

Cyclopenthiazide works by blocking the reabsorption of sodium in the kidneys, leading to increased urine production.

What drug class is CYCLOPENTHIAZIDE in?

CYCLOPENTHIAZIDE belongs to the cyclopenthiazide class. See all cyclopenthiazide drugs at /class/cyclopenthiazide.

What development phase is CYCLOPENTHIAZIDE in?

CYCLOPENTHIAZIDE is in Phase 2.

Drug class: All cyclopenthiazide drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing